EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)

Anlotinib plus toripalimab in patients with advanced bone and soft tissue sarcomas including ultra-rare sarcomas: A multicenter, single-arm, phase 2 trial

Qiuzhong Pan, Bushu Xu, Lihong Zhang, Hui Li, Jingjing Zhao, Xizhi Wen, Jing Yang, Desheng Weng, Ruiqing Peng, Peng Zhang, Xing Zhang

European Journal of Cancer · 2026-07 · 243 · 116871

DOI: 10.1016/j.ejca.2026.116871 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026-07. Verfasst von Qiuzhong Pan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma and sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, China; State Key Laboratory of Oncology in South China, Collaborati…. Hauptthemen laut MEDLINE: Indoles, Quinolines, Sarcoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Treatment options for advanced sarcomas, particularly ultra-rare sarcomas (URS), remain limited. This study evaluated the activity and safety of anlotinib combined with toripalimab in a histologically diverse sarcoma population. METHODS This single-arm, phase 2 clinical trial was conducted at four centers in China. Participants received anlotinib (12 mg on days 1-14) in combination with toripalimab (240 mg on day 1) every 3 weeks. The primary endpoint was objective response rate (ORR) by RECIST 1.1. Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS Of 70 enrolled patients, 68 were evaluable for activity. The cohort included 34 (48.6%) patients with URS. At a median follow-up of 29.6 months, confirmed ORR was 29% (95% CI: 19-42%) and DCR was 90% (95% CI: 80-96%). Median PFS was 7.0 months and median OS was 27.0 months. In patients with soft-tissue URS (n = 31), ORR was 39% and median PFS was 11.0 months. Treatment-related grade ≥ 3 adverse events included hypertension (15.7%), hand-foot syndrome (12.9%), and hypertriglyceridemia (7.1%). Exploratory post-hoc analysis identified baseline monocyte count was independently associated with PFS and OS; responders had significantly lower baseline monocytes than non-responders. CONCLUSIONS These single-arm, exploratory findings demonstrate clinically promising anti-tumor activity for anlotinib plus toripalimab with manageable toxicity in heavily pretreated, histologically diverse advanced sarcomas, highlighting its potential in URS and identifying monocytes as a pragmatic, non-invasive biomarker worthy of further validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndolesQuinolinesSarcomaAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsSoft Tissue NeoplasmsHumansFemaleMaleMiddle AgedAdultAgedYoung AdultProgression-Free SurvivalAdolescent

Stichwörter der Autor:innen

Advanced sarcomasAnlotinibToripalimabUltra-rare sarcomas

Substanzen

anlotinibIndolesQuinolines

Autor:innen und Institutionen

  • Melanoma and sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, China; State Key Laboratory of Oncology in South China, Collaborative innovation Center for Cancer Medicine, Sun Yat-sen University Cance…
  • Department of Oncology, Tongii Hospital, Tongji Medical College, Huazhong University of science and Technology, Wuhan, China.
  • Department of Gastrointestinal Medical Oncology, Clinical Oncology school of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Department of Bone and Soft Tisue, the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China. Electronic address: zdzp@zzu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Pan, Q., Xu, B., Zhang, L., Li, H., Zhao, J., Wen, X., Yang, J., Weng, D., Peng, R., Zhang, P., & Zhang, X. (2026). Anlotinib plus toripalimab in patients with advanced bone and soft tissue sarcomas including ultra-rare sarcomas: A multicenter, single-arm, phase 2 trial. European Journal of Cancer, 243, 116871. https://doi.org/10.1016/j.ejca.2026.116871

Vancouver

Pan Q, Xu B, Zhang L, Li H, Zhao J, Wen X, et al. Anlotinib plus toripalimab in patients with advanced bone and soft tissue sarcomas including ultra-rare sarcomas: A multicenter, single-arm, phase 2 trial. European Journal of Cancer. 2026;243:116871. doi:10.1016/j.ejca.2026.116871

BibTeX
@article{Pan2026,
  author = {Pan, Qiuzhong and Xu, Bushu and Zhang, Lihong and Li, Hui and Zhao, Jingjing and Wen, Xizhi and Yang, Jing and Weng, Desheng and Peng, Ruiqing and Zhang, Peng and Zhang, Xing},
  title = {Anlotinib plus toripalimab in patients with advanced bone and soft tissue sarcomas including ultra-rare sarcomas: A multicenter, single-arm, phase 2 trial},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {243},
  pages = {116871},
  doi = {10.1016/j.ejca.2026.116871}
}
Kostenlos starten →